Can a new drug combination help people with aggressive multiple myeloma? Early results show promise.

For people newly diagnosed with multiple myeloma, the news is especially tough when the cancer has already spread outside the bone marrow—a condition called extramedullary disease. This makes treatment more difficult and the outlook less certain. A recent trial tested a new approach: adding a drug called selinexor to the standard three-drug combination (bortezomib, lenalidomide, and dexamethasone). The goal was to see if this four-drug combo could effectively attack this aggressive form of the disease. The trial involved 29 treated patients. The results were encouraging. Nearly 90% of patients responded to the treatment, with over half achieving a stringent complete response—a deep level of remission where no cancer is detectable by the most sensitive tests. Importantly, imaging scans showed the cancer outside the bone marrow shrank or disappeared in nearly 90% of patients, with complete resolution in about 80%. After one year, about 88% of patients were alive without their cancer getting worse, and over 96% were still alive. The treatment had side effects, with serious ones occurring in about 37% of patients, including low platelet counts and pneumonia, but no deaths were related to the treatment. The manageable side effects allowed over half of the participants to proceed to a stem cell transplant, a potentially curative step. These early findings suggest this four-drug combination is a rational and promising first-line option for patients facing this aggressive myeloma, supporting the need for larger, randomized studies to confirm its benefits.